No. IFS 061/2562 11 November 2019 Subject Management Discussion and Analysis of the 3rd Quarter 2019 Operating Results Dear Governors and President Market for Alternative Investment (mai) Infraset

Discussion & Analysis Q3/2022 Operating Highlights in Q3/2022 Q3/21 Q3/22 Change +/(-) 9M/21 9M/22 Change +/(-) (THB million) %YoY %YoY Operating Revenue 115 246 114% 431 674 56% Gross Profit 60 159 165% 242

. DOD2019/004 February 20, 2019 Subject: Management’s discussion and analysis of the Company’s operating results for the year 2018 period To: President The Stock Exchange of Thailand DOD Biotech Public

/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

-collect, same day, or next day delivery. The Company has rapidly reshaped and reallocated the resources to facilitate its operations to meet a material increase in online transactions. Operating Results

- 1 - AIT (VP-SEC) 004E/2020 February 11, 2021 Subject: Management's Discussion and Analysis of Operating Results for the year 2020 and Q4-2020 To: The President of the Stock Exchange of Thailand

-1- AIT (VP-SEC) 003E/2023 16 February 2023 Subject: Management's Discussion and Analysis of Operating Results for the year 2022 and Q4-2022 To: The President of the Stock Exchange of Thailand

resolved to approve the cash dividend payment from the operating results of 2H 17/18 at THB 0.054 per share (subject to the resolution of 2018 Annual General Meeting of Shareholders, which will be held on 5

Summary Significant Event Operating Highlights in Q1/2023 Q2/22 Q2/23 Change +/(-) 1H/22 1H/23 Change +/(-) (THB million) %YoY %YoY Operating Revenue 230 299 30% 428 563 32% Gross Profit 147 192 31% 267 361

Summary Significant Event Operating Highlights in Q3/2023 Q3/22 Q3/23 Change +/(-) 9M/22 9M/23 Change +/(-) (THB million) %YoY %YoY Operating Revenue 246 338 37% 674 900 34% Gross Profit 159 223 40% 426 583